Novacyt (France) Today
| ALNOV Stock | EUR 0.58 0.01 1.69% |
Performance0 of 100
| Odds Of DistressLess than 10
|
Novacyt is selling at 0.58 as of the 24th of November 2024; that is 1.69 percent down since the beginning of the trading day. The stock's last reported lowest price was 0.57. Novacyt has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Novacyt are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of September 2024 and ending today, the 24th of November 2024. Click here to learn more.
Novacyt S.A. develops and sells diagnostic products for cancer and infectious diseases. The company was founded in 2006 and is based in Vlizy-Villacoublay, France. NOVACYT operates under Biotechnology classification in France and is traded on Paris Stock Exchange. The company has 70.63 M outstanding shares. More on Novacyt
Moving together with Novacyt Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Novacyt Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Novacyt's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Novacyt or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Novacyt (ALNOV) is traded on Euronext Paris in France and employs 210 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 48.96 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Novacyt's market, we take the total number of its shares issued and multiply it by Novacyt's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Novacyt operates under Biotechnology sector and is part of Health Care industry. The entity has 70.63 M outstanding shares.
Novacyt has accumulated about 101.75 M in cash with 15.69 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.03.
Check Novacyt Probability Of Bankruptcy
Ownership AllocationNovacyt maintains a total of 70.63 Million outstanding shares. Novacyt secures 3.49 % of its outstanding shares held by insiders and 1.6 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Novacyt Ownership Details
Novacyt Risk Profiles
Although Novacyt's alpha and beta are two of the key measurements used to evaluate Novacyt's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.75 | |||
| Standard Deviation | 5.6 | |||
| Variance | 31.41 | |||
| Risk Adjusted Performance | (0.12) |
Novacyt Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Novacyt without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Premium Stories Now
Premium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
| All Next | Launch Module |
Novacyt Corporate Management
Elected by the shareholders, the Novacyt's board of directors comprises two types of representatives: Novacyt inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novacyt. The board's role is to monitor Novacyt's management team and ensure that shareholders' interests are well served. Novacyt's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novacyt's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steve Gibson | Member of the Executive Team, Group Financial Controller | Profile | |
| David Franks | Chief Officer | Profile | |
| Grald Ulrich | Chief Devel | Profile | |
| James McCarthy | Acting CFO | Profile | |
| Wendy Karban | Member of the Executive Team, Group Human Resource Manager | Profile | |
| Bryan Close | Chief Officer | Profile | |
| Paul Oladimeji | Group RD | Profile |
Additional Tools for Novacyt Stock Analysis
When running Novacyt's price analysis, check to measure Novacyt's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novacyt is operating at the current time. Most of Novacyt's value examination focuses on studying past and present price action to predict the probability of Novacyt's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novacyt's price. Additionally, you may evaluate how the addition of Novacyt to your portfolios can decrease your overall portfolio volatility.